Expression of a kinase-deficient IGF-I-R suppresses tumorigenicity of rhabdomyosarcoma cells constitutively expressing a wild type IGF-I-R

International Journal of Cancer

Volumn 76, Issue 2, 1998, Pages 223-227

  Kalebic, Thea ^a   Blakesley, Vicky ^b   Slade, Crystal ^a   Plasschaert, Sabine ^a   Leroith, Derek ^b   Lee Helman, J ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

^b Diabetes Branch   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PHOSPHOTRANSFERASE; SOMATOMEDIN C; SOMATOMEDIN C RECEPTOR;

AMINO ACID SUBSTITUTION; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; AUTOPHOSPHORYLATION; CANCER INHIBITION; CARCINOGENICITY; CONTROLLED STUDY; FLUORESCENCE ACTIVATED CELL SORTER; GENE EXPRESSION; GENE MUTATION; HUMAN; HUMAN CELL; MOUSE; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; RHABDOMYOSARCOMA;

CELL DIVISION; HUMANS; INSULIN-LIKE GROWTH FACTOR I; MACROMOLECULAR SUBSTANCES; MUTATION; PHOSPHORYLATION; RECEPTOR, IGF TYPE 1; RHABDOMYOSARCOMA; STIMULATION, CHEMICAL; TRANSFECTION; TUMOR CELLS, CULTURED; TUMOR STEM CELLS;

EID: 0032513524     PISSN: 00207136     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1097-0215(19980413)76:2<223::AID-IJC9>3.0.CO;2-Z     Document Type: Article

References (22)

1. ARTEAGA, C.L., Interference of the IGF system as a strategy to inhibit breast cancer growth. Breast Cancer Res. Treat., 22, 101-106 (1992).
2. BASERGA, R., The insulin-like growth factor I receptor: a key to tumor growth? Cancer Res., 55,249-252 (1995).
3. BLAKESLEY, V.A., KALEBIC, T., HELMAN, L.J., STANNARD, B., FARIA, T.N., ROBERTS, C.J. and LEROITH, D., Tumorigenic and mitogenic capacities are reduced in transfected fibroblasts expressing mutant insulin-like growth factor (IGF)-I receptors. The role of tyrosine residues 1250, 1251, and 1316 in the carboxy-terminus of the IGF-I receptor. Endocrinology, 137, 410-417 (1996).
4. D'AMBROSIO, C., FERBER, A., RESNICOFF, M. and BASEROA, R., A soluble insulin-like growth factor I receptor that induces apoptosis of tumor cells in vivo and inhibits tumorigenesis. Cancer Res., 56, 4013-4020 (1996).
5. DE GIOVANNI, C, MELANT, C., NANNI, P., LANDUZZI, L., NICOLETTI, G., FRABETTI, E, GRIFFONI, C., COLOMBO, M.P. and LOLLINI, P.L., Redundancy of autocrine loops in human rhabdomyosarcoma cells: induction of differentiation by suramin. Brit. J. Cancer, 72,1224-1229 (1995).
6. EL-BADRY, O.M., MINNITI, C.P., KOHN, E.C., HOUGIITON, P.J., DAUGHADAY, W.H. and HELMAN, L.J., Insulin-like growth factor II acts as an autocrine growth and motility factor in human rhabdomyosarcoma tumors. Cell Growth Differentiation., 1,325-331 (1990).
7. HERNANDEZ, S.C., BLAKESLEY, V., KALEBIC, T., HELMAN, L. and LEROITH, D., The role of the tyrosine kinase domain of the insulin-like growth factor-I receptor in intracellular signaling, cellular proliferation, and tumorigenesis. J. biol. Cliem., 270,29176-29181 (1995).
8. KALEBIC, T., JUDDE, J., VELEZ-YANGUAS, M., KNUTSEN, T. and HELMAN, L.,
9. Metastatic human rhabdomyosarcoma: molecular, cellular and cytogenetic analysis of a novelcellular model. Invasion Metastasis, 16,83-96 (1996).
10. KALEBIC, T., TSOKOS, M. and HELMAN, L.J., In vivo treatment with antibody against IGF-I receptor suppresses growth of human rhabdomyosarcoma and down regulates p34cdc2. Cancer Res., 54,5531-5534 (1994).
11. KALEKO, M., RUTTER, W.T. and MILLER, A.D., Overexpression of the human insulinlike growth factor I receptor promotes ligand-dependent neoplastic transformation. Mol. cell. Biol, 10,464-473 (1990).
12. KATO, H., FARIA, T.N., STANNARD, B., ROBERTS, C.J. and LEROITH, D., Role of tyrosine kinase activity in signal transduction by the insulin-like growth factor-I (IGF-I) receptor. Characterization of kinase-deficient IGF-I receptors and the action of an IGF-I-mimetic antibody (alpha IR-3). J. biol. Chem., 268,2655-2661 (1993).
13. LEROITH, D., WERNER, H., NEUENSCHWANDER, S., KALEBIC, T. and HELMAN, L.J., The role of the insulin-like growth factor-I receptor in cancer. Ann. N. Y. Acad. Sci., 766, 402-408 (1995).
14. PRAGER, D., LI, H.L., ASA, S. and MELMED, S., Dominant negative inhibition of tumorigenesis in vivo by human insulin-like growth factor I receptor mutant. Proc. not. Acad. Sei. (Wash.), 91,2181-2185 (1994).
15. RESNICOFF, M., BURGAUD, J.L., ROTMAN, H.L., ABRAHAM, D. and BASERGA, R-, Correlation between apoptosis, tumorigenesis, and levels of insulin-like growth factor I receptors. Cancer Res., 55, 3739-3741 (1995).
16. RODRIGUEZ, T.G., COLLINS, M.K., GARCIA, I. and LOPEZ, R.A., Insulin-like growth factor-I inhibits apoptosis in IL-3-dependent hemopoietic cells. J. Immuiwl, 149,535-540 (1992).
17. SCOTLANDI, K., BENINI, S., SARTI, M., SERRA, M., LOLLINI, P.L., MAURICI, D., PICCI, P., MANARA, M.C. and BALDINI, N., Insulin-like growth factor I receptor-mediated circuit in Ewing's sarcoma/peripheral neuroectodermal tumor: a possible therapeutic target. Cancer Res., 56, 4570-4574 (1996).
18. SHAPIRO, D.N., JONES, E.G., SHAPIRO, L.H., DIAS, P. and HOUGHTON, P.J., Antisense-mediated reduction in insulin-like growth factor-I receptor expression suppresses the malignant phenotype of a human alveolar rhabdomyosarcoma. J. din. Invest., 94,1235-1242 (1994).
19. SURMACZ, E., SELL C., SWANTEK J., KATO H., ROBERTS C.T., LEROITH D. and BASERGA R., Dissociation of mitogenesis and transforming activity by C-terminal truncation of the insulin-like growth factor-I receptor. Exp. Cell. Res., 218,380-380 (1995).
20. TORETSKY, J.A. and HELMAN, L.J., Involvement of IGF-II in human cancer. J. Endocrinol., 149, 367-372 (1996).
21. TROJAN, J., JOHNSON, T.R., RUDIN, S.D., ILAN, J., TYKOCINSKI, M.L. and ILAN, J., Treatment and prevention of rat glioblastoma by immunogenic C6 cells expressing antisense insulin-like growth factor I RNA. Science, 259, 94-97(1993).
22. ULLRICH, A. and 12 OTHERS, Insulin-like growth factor I receptor primary structure: comparison with insulin receptor suggests structural determinants that define functional specificity. EMBO J., 5, 2503-2512 (1986).